"5"^^ . "10" . "Recidiva tromboembolick\u00E9 nemoci a mo\u017Enosti jej\u00ED prevence" . . "Anticoagulation treatment; Bleeding; Thromboembolic disease"@en . "I" . . "91" . "MEMO01Pacienti po prod\u011Blan\u00E9 trombolembolick\u00E9 p\u0159\u00EDhod\u011B maj\u00ED zv\u00FD\u0161en\u00E9 riziko recidivy, ale riziko nen\u00ED stejn\u00E9 u v\u0161ech pacient\u016F. V sou\u010Dasn\u00E9 dob\u011B m\u00E1me k dispozici \u00FA\u010Dinn\u00E9 antikoagula\u010Dn\u00ED l\u00E9ky, probl\u00E9mem ale z\u016Fst\u00E1v\u00E1 riziko krv\u00E1cen\u00ED. P\u0159i posuzov\u00E1n\u00ED indikace a trv\u00E1n\u00ED sekund\u00E1rn\u00ED profylaxe mus\u00ED b\u00FDt v rovnov\u00E1ze riziko opakov\u00E1n\u00ED a riziko krv\u00E1cen\u00ED. Warfarin je nejroz\u0161\u00ED\u0159en\u011Bj\u0161\u00ED peror\u00E1ln\u00ED antikoagula\u010Dn\u00ED l\u00E9k, ale pro dlouh\u00FD polo\u010Das je po\u010D\u00E1te\u010Dn\u00ED nastaven\u00ED l\u00E9\u010Dby pomal\u00E9, vy\u017Eaduje \u010Dast\u00E9 laboratorn\u00ED kontroly a \u00FApravy d\u00E1vkov\u00E1n\u00ED. Nov\u00E1 peror\u00E1ln\u00ED antikoagulancia mohou b\u00FDt pod\u00E1v\u00E1na ve fixn\u00EDch d\u00E1vk\u00E1ch bez nutnosti laboratorn\u00EDho sledov\u00E1n\u00ED, a proto budou v klinick\u00E9 praxi vhodn\u011Bj\u0161\u00ED pro sekund\u00E1rn\u00ED profylaxi."@cs . . "RIV/00064203:_____/11:7233" . "Chlumsk\u00FD, Jarom\u00EDr" . "1"^^ . . . "Praktick\u00FD l\u00E9ka\u0159" . "Recidiva tromboembolick\u00E9 nemoci a mo\u017Enosti jej\u00ED prevence"@cs . "[8E3BF1F90CE8]" . . "CZ - \u010Cesk\u00E1 republika" . "1"^^ . . . "Recidiva tromboembolick\u00E9 nemoci a mo\u017Enosti jej\u00ED prevence" . "Recurrence of thromboembolic disease and the possibility of its prevention"@en . . . . "MEMO01Pacienti po prod\u011Blan\u00E9 trombolembolick\u00E9 p\u0159\u00EDhod\u011B maj\u00ED zv\u00FD\u0161en\u00E9 riziko recidivy, ale riziko nen\u00ED stejn\u00E9 u v\u0161ech pacient\u016F. V sou\u010Dasn\u00E9 dob\u011B m\u00E1me k dispozici \u00FA\u010Dinn\u00E9 antikoagula\u010Dn\u00ED l\u00E9ky, probl\u00E9mem ale z\u016Fst\u00E1v\u00E1 riziko krv\u00E1cen\u00ED. P\u0159i posuzov\u00E1n\u00ED indikace a trv\u00E1n\u00ED sekund\u00E1rn\u00ED profylaxe mus\u00ED b\u00FDt v rovnov\u00E1ze riziko opakov\u00E1n\u00ED a riziko krv\u00E1cen\u00ED. Warfarin je nejroz\u0161\u00ED\u0159en\u011Bj\u0161\u00ED peror\u00E1ln\u00ED antikoagula\u010Dn\u00ED l\u00E9k, ale pro dlouh\u00FD polo\u010Das je po\u010D\u00E1te\u010Dn\u00ED nastaven\u00ED l\u00E9\u010Dby pomal\u00E9, vy\u017Eaduje \u010Dast\u00E9 laboratorn\u00ED kontroly a \u00FApravy d\u00E1vkov\u00E1n\u00ED. Nov\u00E1 peror\u00E1ln\u00ED antikoagulancia mohou b\u00FDt pod\u00E1v\u00E1na ve fixn\u00EDch d\u00E1vk\u00E1ch bez nutnosti laboratorn\u00EDho sledov\u00E1n\u00ED, a proto budou v klinick\u00E9 praxi vhodn\u011Bj\u0161\u00ED pro sekund\u00E1rn\u00ED profylaxi." . . "0032-6739" . . . "Recurrence of thromboembolic disease and the possibility of its prevention"@en . "RIV/00064203:_____/11:7233!RIV12-MZ0-00064203" . "225940" . . "MEMO01Patients with an initial VTE event are at an increased risk for recurrence, but the risk is not equivalent in all patients. Currently available anticoagulation therapies are effective in reducing VTE recurrence, they are associated with bleeding risks. When assessing the need for and duration of secondary prophylaxis the risk for recurrence needs to be balanced with the risk for bleeding. Warfarin is the most widely used oral anticoagulation agent but is inconvenient in the setting of long-term prophylaxis as it requires frequent monitoring and dose adjustments. New oral anticoagulant agents can be given in fixed doses without the need for coagulation monitoring hold the promise of being more convenient for secondary prophylaxis"@en . "Recidiva tromboembolick\u00E9 nemoci a mo\u017Enosti jej\u00ED prevence"@cs . "http://www.medvik.cz/link/bmc12000095" .